These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 12038784

  • 1. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys.
    McCarthy K, Stewart P, Sigman J, Read M, Keith JC, Brinkhous KM, Nichols TC, Schaub RG.
    Thromb Haemost; 2002 May; 87(5):824-30. PubMed ID: 12038784
    [Abstract] [Full Text] [Related]

  • 2. Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs.
    Russell KE, Read MS, Bellinger DA, Leitermann K, Rup BJ, McCarthy KP, Keith JC, Khor SP, Schaub RG, Nichols TC.
    Thromb Haemost; 2001 Mar; 85(3):445-9. PubMed ID: 11307812
    [Abstract] [Full Text] [Related]

  • 3. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
    Nolte MW, Nichols TC, Mueller-Cohrs J, Merricks EP, Pragst I, Zollner S, Dickneite G.
    J Thromb Haemost; 2012 Aug; 10(8):1591-9. PubMed ID: 22726310
    [Abstract] [Full Text] [Related]

  • 4. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
    Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, Leppanen SD, Rup BJ, Keith JC, Garzone PD, Schaub RG.
    Blood; 1996 Oct 01; 88(7):2603-10. PubMed ID: 8839853
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
    Preijers T, Bukkems L, van Spengler M, Leebeek F, Cnossen M, Mathôt R.
    Eur J Clin Pharmacol; 2021 Aug 01; 77(8):1193-1200. PubMed ID: 33624121
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs.
    Russell KE, Olsen EH, Raymer RA, Merricks EP, Bellinger DA, Read MS, Rup BJ, Keith JC, McCarthy KP, Schaub RG, Nichols TC.
    Blood; 2003 Dec 15; 102(13):4393-8. PubMed ID: 12933577
    [Abstract] [Full Text] [Related]

  • 14. Preclinical studies of recombinant factor IX.
    Schaub R, Garzone P, Bouchard P, Rup B, Keith J, Brinkhous K, Larsen G.
    Semin Hematol; 1998 Apr 15; 35(2 Suppl 2):28-32. PubMed ID: 9565164
    [Abstract] [Full Text] [Related]

  • 15. Clinical evaluation of recombinant factor IX.
    White G, Shapiro A, Ragni M, Garzone P, Goodfellow J, Tubridy K, Courter S.
    Semin Hematol; 1998 Apr 15; 35(2 Suppl 2):33-8. PubMed ID: 9565165
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
    Nummi V, Jouppila A, Lassila R.
    Int J Lab Hematol; 2017 Aug 15; 39(4):359-368. PubMed ID: 28406575
    [Abstract] [Full Text] [Related]

  • 18. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
    Wilmot HV, Hogwood J, Gray E.
    Haemophilia; 2014 Nov 15; 20(6):891-7. PubMed ID: 24800651
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.